great site Update-1…1/21/19 Liquid Biopsy I attended a Panel Session on Cancer Liquid Biopsy and although progress is being made on molecular diagnostics there are no newsworthy breakthroughs nor actual data showing a hard timeline. Here is an article from BIO 2016. There are over 70 genes that need to be tested and voluminous data is being generated […]

Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ Rallies 0.79% on Nov 30 Our recent […]

Update at Close 11/9/18 Remain Cautious as Rally Fails The NASDAQ down 1.6% and Russell 2000 down 1.8%, sold off killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. The healthcare still looks good overall with the XLV down only 0.29% at $92.95. The XBI was crushed again down […]

Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology because […]

Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]

Update 9/26: FED Rate Hike Curbs Traders but Biotech Rolls On The market dipped slightly then went red about 3:30P EDT resulting in a 0.4% loss for the Dow. Main rates will rise to the 2 to 2.25% level with more rate hikes in the future. During Trump’s Press Conference today he said he does not […]

Biotechs Bounce Back: Up From September Lows-Markets Surge Ahead XBI Up 1.66% to $97.16 up from 3 month tech support of $95;IBB up 1.39%. Broad rally brings Dow up 1%, S&P up 0.81% to fresh highs-strong 4 mo. trend line. Sector Winners: Tech (XLK) up 1.18%, Materials (XLB) up 1.08%, Healthcare (XLV) new high up […]

Contact Us

Raygent Associates

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

About the Author

Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.